Plain-English translation of NCT06747845 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether two drugs called and work together to slow pancreatic cancer growth in people whose cancer has not gotten worse after standard chemotherapy. You would receive this medication every 3 weeks, or you might receive standard chemotherapy every 2 weeks instead, depending on which group you're randomly assigned to. The study wants to learn whether this new treatment combination is more effective and how safe it is.
Pancreatic cancer is very difficult to treat, and many patients' cancers return or continue to grow despite chemotherapy. Researchers believe that combining these two types of drugs—one that helps repair cancer cells and another that boosts the immune system—may work better than chemotherapy alone to control the disease long-term.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will have screening tests to confirm your cancer type and overall health. Then you'll be randomly assigned to receive either the new medication combination every 3 weeks or standard chemotherapy every 2 weeks. You'll need to visit the clinic regularly for checkups, blood tests, and imaging scans to see how your cancer is responding. Before starting and during treatment, you may need to have small tumor biopsies taken, which involves a needle procedure to collect a tiny tissue sample.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
United States